Table 1.
Summary of ERβ survival analysis of lung tumor tissue by IHC
| Study Name | ERβ Ab | Sample Size | Stage Distribution | Scoring System | Result |
|---|---|---|---|---|---|
| Wu 2005 (ref. 13) | Biogenix (ERβ-1 isoform specific) | Male 174 | Stage I 38% | nuclear staining only scored | Positive ERβ=lower grade tumor in men and women combined |
| Female 127 | Stage II 22% | positive = moderate/strong nuclear staining of >50% of tumor cells | ERβ overexpression= better survival | ||
| Total 301 | stage III 40% | negative = not defined | |||
| cut-off= positive versus negative | |||||
| Schw artz 2005 (ref. 14) | MCA 1974 (ERβ-1 isoform specific) | Male 64 | Local 21.9% | nuclear and cytoplasmic staining scored together | Positive ERβ= better survival in men (significant) |
| Female 214 | Regional/Distant 64.7% | % positive cells (focal <10%, moderate 11-50%, diffuse 41-100%) + staining intensity (1-3) | Positive ERβ= worse survival in women (trend) | ||
| Total 278 | Unknown 13.3% | positive = at least +1 (weak) intensity in ≥ 10%of tumor cells | |||
| negative = no nuclear staining, cytoplasmic staining or +1 intensity nuclear staining | |||||
| cut-off= positive versus negative | |||||
| Kaw aii 2005 (ref. 15) | H-150 (epitope-aa 1-150 of ERβ) | Male 76 | Stage I 50% | not specified if nuclear or cytoplasmic ERβ was examined | Positive ERβ= better survival in men and women combined |
| Female 56 | Stage II 18% | % positive score (0-5) + staining intensity (0-3)= total score (0-8) | High ERβ= better survival in men and women combined (Stage I only) | ||
| Total 132 | Stage III 27% | positive = not defined | |||
| Stage IV 5% | negative= not defined | ||||
| cut-off= positive versus negative and low (0-4) versus high (5-8) | |||||
| Skov 2005 (ref. 16) | PPG5/10 (ERβ-1 isoform specific) | Male 71 | Stage I 63% | nuclear staining only scored | Negative ERβ= better survival in women |
| Female 33 | Stage II 13% | positive= at least weak nuclear staining in >10% of tumor cells | Positive ERβ= better survival in men | ||
| Total 104 | Stage III 26% | negative= not defined | no clinical signficance with cytoplasmic ERβ in separate analysis | ||
| cut-off= positive versus negative | |||||
| Nose 2009 (ref. 60) | H-150 (epitope-aa 1-150 of ERβ) | Male 260 | Stage I 64% | nuclear staining only scored | Strong nuclear ERβ=better DFS in all patients |
| Female 187 | Stage II 9% | % positive score (0-5) + staining intensity (0-3)= total score (0-8) | Strong nuclear ERβ= better DFS in patients with EGFR mutant tumors, but not EGFR wild-type tumors | ||
| Total 447 | Stage III 23% | negative= 0 | |||
| Stage IV 4% | weak= 2-4 | ||||
| strong= 5-8 | |||||
| cut-off= negative/weak versus strong | |||||
| Raso 2009 (ref. 67) | H-150 (epitope-aa 1-150 of ERβ) | Male 150 | Stage I 63% | nuclear and cytoplasmic staining scored separately | Low nuclear ERβ= better RFS |
| Female 167 | Stage II 20% | % positive score (0-100%) X staining intensity (0-3)= total score (0-300) | no relationship with OS | ||
| Total 317 | Stage III 15% | positive= >0 | |||
| Stage IV 2% | negative=0 | ||||
| cut-off= low (0) versus high (>0) | |||||
| Stabile 2011 (ref. 20) | PPG5/10 (ERβ-1 isoform specific) | Male 91 | Stage I 39% | nuclear and cytoplasmic staining scored separately | High cytoplasmic ERβ=worse OS and shorter TTP |
| Female 92 | Stage II 20% | % positive score (0-5) + staining intensity (0-3)= total score (0-8) | no relationship with nuclear ERβ | ||
| Total 183 | Stage III 28% | low= 0-7 | ERβ associated with poor survival was in the strongest staining group only (>7) | ||
| Stage IV 11% | high=>7 | Survival effect may be for ERβ-1 overexpressing tumors only | |||
| Unknown 1% | cut-off= low versus high | ||||
| Navaratnam 2012 (ref. 22) | GC17/385P (ERβ-1 isoform specific) | Male 70 | Stage I-II 64% | nuclear staining only scored | High ERβ-1= better OS in earlier stage |
| 14C8 (total ERβ) | Female 67 | Stage III-IV 36% | nuclear staining intensity (1-3) X % tumor cells stained | High ERβ-1=worse OS in later stage | |
| 57/3 (ERβ-2 isoform specific) | Total 137 | cut-off= median IHC score | no relationship with ERβ-2 | ||
| Liu 2013 (ref. 23) | PPG5/10 (ERβ-1 isoform specific) | Male 58 | Stage I-II 36% | nuclear and cytoplasmic staining scored separately | cytoplasmic ERβ-2 and ERβ-5=longer DFS and OS |
| 57/3 (ERβ-2 isoform specific) | Female 54 | Stage III-IV 64% | % positive score (0-5) + staining intensity (0-3)= total score (0-8) | ||
| Total 112 | cut-off = Allred score>3 | ||||
| DFS, disease-free survival; RFS, recurrance-free survival; PFS, progression-free survival; OS, overall survival; TTP, time to progression | |||||